Updated Testing Algorithms for Plasma Cell Proliferative Disorders: Xinjie Xu, Ph.D.

Xinjie Xu, Ph.D., a cytogeneticist and a molecular geneticist who specializes in genetic testing for hematological malignancies, explains Mayo Clinic Laboratories' updated approach to genetic testing for risk stratification of patients newly diagnosed with plasma cell proliferative disorders, such as multiple myeloma. Based on recently published data, the new testing algorithms focus on use of fluorescence in situ hybridization (FISH) panels, rather than chromosome studies.

Show Notes

Tell us a little bit about your background and about yourself.
 
Give us a brief overview of what are the previous approaches that have been used in the past for multiple myeloma testing.
 
So can you take a moment and talk to me about the new approach and the new algorithm that your laboratory is working on implementing?

 

So how does this new approach really benefit both hospitals across the country that we serve and the patients that they're trying to treat?

 

What else is the lab working on when it comes to our multiple myeloma testing and our algorithms?
 
 

Resources
Plasma Cell Proliferative Disorder [A Test in Focus]

Plasma Cell Proliferative Disorder, FISH, Bone Marrow (Mayo test ID: PCPDS)

Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow (Mayo test ID: MSMRT)

Chromosome Analysis, Hematologic Disorders, Bone Marrow (Mayo test ID: CHRBM)

Mellors et al.: Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances. 2020;4(10): 2236-2244 

What is Answers from the Lab?

A Mayo Clinic curated podcast sharing Mayo Clinic knowledge and advancements on the state of testing, science, and people who are making it happen behind the scenes.